The expanded EUA is based on results from a Phase III trial evaluating Veklury in hospitalised patients with moderate COVID-19 pneumonia, as well as results from a
The drug is an investigational nucleotide analogue with broad-spectrum antiviral activity both in vitro and in vivo in animal models against multiple emerging viral pathogens.
Gilead conducted two randomised, open-label, multi-centre international Phase III clinical trials for the investigational drug in countries with a high prevalence of COVID-19 infections. The data published demonstrated that Veklury was generally well-tolerated in both five-day and 10-day treatment groups.
"With the growing understanding of the utility of Veklury to help improve outcomes for a range of patients with COVID-19, we welcome the
"As our understanding of the spectrum of SARS-CoV-2 infection and the presentations and severity of COVID-19 continues to evolve, these results and the expanded EUA represent a new, important step that streamlines bedside prescribing of remdesivir without having to wait for patients to worsen clinically," said Dr
The post FDA expands emergency use authorisation for remdesivir to treat all COVID-19 patients appeared first on European Pharmaceutical Review.
© Russell Publishing Limited, 2020. All Rights Reserved., source